← The patent line

Avacincaptad Pegol Sodium

Sold as IZERVAY · given by intravitreal

Five to ten years until it comes off patent
7.9 yr
Until anyone may copy it
Protection runs to 2034-07-11
3
Trials running now
14 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Astellas Pharma Us Inc
Approval holder
the only company permitted to sell it today
2034-07
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Geographic AtrophyNeovascular Age-Related Macular DegeneMacular Degeneration
03

Who is paying for the research

Ophthotech Corporation
Company
5
Astellas Pharma Global Development
Company
3
IVERIC bio, Inc.
Company
3

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT06659445Phase 22025 · 324 people · recruiting now
Study to Evaluate Efficacy and Safety of ONL

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line